Iambic Therapeutics

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

Iambic Therapeutics headquartered in United States, North America, operates in the Software, Artificial Intelligence (AI), Machine Learning, Therapeutics sector. The company focuses on Software and has secured $9.7B in funding across 48 round(s). With a team of 51-100 employees, Iambic Therapeutics is actively contributing to advancements in Software. Their latest funding round, Series B - Iambic Therapeutics, raised $50.0M. Discover more about their projects, partnerships, and impact on our platform.